<DOC>
	<DOCNO>NCT00091806</DOCNO>
	<brief_summary>The purpose study evaluate safety pharmacokinetics two dose schedule panitumumab subject advance solid tumor .</brief_summary>
	<brief_title>Two Dose Schedules Panitumumab Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Pathologic diagnosis advance solid tumor refractory least 1 standard therapy standard therapy available receive 3 prior treatment regimen ( inclusive hormonal therapy breast prostate cancer subject ) advance solid tumor ( tumor must diagnose standard criterion specific tumor type ) Measurable disease evaluable ( nonmeasurable ) disease per RECIST guideline ( sites disease must evaluate within 28 day enrollment ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy &gt; 3 month document investigator If history primary cancer , subject eligible : Nonmelanomatous skin cancer , require treatment Curatively treat cervical carcinoma situ Other primary solid tumor curatively treat know active disease present last 5 year treatment administer last 3 year Man woman 18 year age old Paraffinembedded tumor tissue ( primary metastatic tumor tissue ) available immunohistochemistry study EGFr expression ( biopsy archive tissue acceptable ) . The immunohistochemical EGFr stain evaluation must conduct designated central laboratory use DakoCytomation EGFR pharmDXTM kit . Local laboratory EGFr expression permit purpose eligibility study Hematologic function , follow : Absolute neutrophil count ( ANC ) &gt; 1.5 x 109/L Platelet count &gt; 100 x 109/L Hemoglobin &gt; 8 g/dL Renal function , follow : Creatinine &lt; 2.0 mg/dL Hepatic function , follow : Aspartate aminotransferase ( AST ) &lt; 3 x ULN ( liver metastasis ≤ 5 x ULN ) Alanine aminotransferase ( ALT ) &lt; 3 x ULN ( liver metastasis ≤ 5 x ULN ) Bilirubin &lt; 2 x ULN Competent comprehend , sign , date IEC/IRBapproved inform consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Targeted Therapy</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>ABX-EGF , panitumumab</keyword>
	<keyword>EGFr</keyword>
	<keyword>Immunex , Abgenix , Amgen</keyword>
	<keyword>Monoclonal Antibody</keyword>
</DOC>